Search Results - "Ichikawa W"

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.

Authors: Ichikawa, W Uehara, K Minamimura, K et al.

Source: British Journal of Cancer. 5/12/2015, Vol. 112 Issue 10, p1709-1716. 8p. 2 Charts, 4 Graphs.

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.

Authors: Ichikawa, W. Takahashi, T. Suto, K. et al.

Source: British Journal of Cancer. 10/04/2004, Vol. 91 Issue 7, p1245-1250. 6p.

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors: Ichikawa, W. Uetake, H. Shirota, Y. et al.

Source: British Journal of Cancer. 10/20/2003, Vol. 89 Issue 8, p1486-1492. 7p.

Phase II study of FOLFOX4 with 'wait and go' strategy as first-line treatment for metastatic colorectal cancer.

Authors: Kochi M Ichikawa W Meguro E et al.

Source: Cancer Chemotherapy & Pharmacology. Nov2011, Vol. 68 Issue 5, p1215-1222. 8p.

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

Authors: Sunakawa Y Ichikawa W Fujita K et al.

Source: Cancer Chemotherapy & Pharmacology. Aug2011, Vol. 68 Issue 2, p279-284. 6p.

685PRelation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer.

Authors: Takeuchi, M Ichikawa, W Shitara, K et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

O2–089NOMOGRAM FOR PREDICTION OF TOXICITIES IN ADVANCED COLORECTAL CANCER (aCRC) TREATED WITH IRINOTECAN (IRI)-BASED REGIMENS.

Authors: Ichikawa, W. Uehara, K. Minamimura, K. et al.

Source: Annals of Oncology. Nov2013 Supplement 9, Vol. 24, pix54-ix54. 1p.

Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.

Authors: Fujita, K. Ichikawa, W. Yamamoto, W. et al.

Source: Annals of Oncology. May2009, Vol. 20 Issue 5, p946-946. 1p.

827P Impact of conversion surgery (CS) on the prognostic value of depth of response (DpR) in patients with metastatic colorectal cancer (mCRC): A post-hoc analysis of the DEEPER trial (JACCRO CC-13).

Authors: Mihara, Y. Pak, K. Sunakawa, Y. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS559-S560. 2p.

839P Encorafenib, cetuximab, plus binimetinib combination therapy for BRAF-mutated metastatic colorectal cancer (mCRC) with prognostic factors: The BEETS trial (JACCRO CC-18).

Authors: Sunakawa, Y. Inoue, E. Kotani, D. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS566-S566. 1p.

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.

Authors: Inokuchi, M. Yamashita, T. Yamada, H. et al.

Source: British Journal of Cancer. 4/24/2006, Vol. 94 Issue 8, p1130-1135. 6p. 4 Charts, 1 Graph.

35P Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS/BRAF wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).

Authors: Sunakawa, Y. Shiozawa, M. Shindo, Y. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS20-S20. 1p.

20P Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18).

Authors: Inagaki, C. Matoba, R. Inoue, E. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS14-S14. 1p.

MO40-1 Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13).

Authors: Natsume, S. Sekikawa, T. Takagane, A. et al.

Source: Annals of Oncology. Oct2024:Supplement 3, Vol. 35, pS1348-S1348. 1p.

525P Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody.

Authors: Sugiyama, K. Yasui, H. Nakamura, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS442-S442. 1p.

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).

Authors: Tanabe, K. Fujii, M. Nishikawa, K. et al.

Source: Annals of Oncology. Sep2015, Vol. 26 Issue 9, p1916-1922. 7p. 1 Diagram, 4 Charts, 1 Graph.

O2–084A COMPARISON OF FOUR METHODS FOR DETECTING KRAS MUTATIONS IN FORMALIN-FIXED COLORECTAL CANCER SPECIMENS.

Authors: Miwa, K. Fujita, K.-i. Ichikawa, W. et al.

Source: Annals of Oncology. Nov2013 Supplement 9, Vol. 24, pix54-ix54. 1p.

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

Authors: Sunakawa, Y. Tsuji, A. Fujii, M. et al.

Source: Annals of Oncology. Aug2017, Vol. 28 Issue 8, p2030-2032. 3p. 1 Graph.

594P The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy.

Authors: Izawa, N. Kudo, T. Yuki, S. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS430-S430. 1p.

555MO Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13).

Authors: Sunakawa, Y. Shiozawa, M. Watanabe, T. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS414-S414. 1p.